Outcomes in patients with anthracycline-induced cardiomyopathy undergoing left ventricular assist devices implantation.

Avirup GuhaCesar CaraballoPrantesh JainP Elliott MillerJocelyn Owusu-GuhaKatherine A A ClarkEric J VelazquezTariq AhmadLauren A BaldassarreDaniel AddisonNeal L WeintraubNihar R Desai

Published in: ESC heart failure (2021)

After receiving a CF-LVAD, survival in patients with anthracycline-induced cardiomyopathy is similar to those with ICM or IDM. Further research into differential secondary endpoints-related disparities is warranted.

Keyphrases

heart failure
left ventricular
high glucose
diabetic rats
cystic fibrosis
drug induced
metabolic syndrome
adipose tissue
healthcare
type diabetes
coronary artery disease
skeletal muscle
acute coronary syndrome
stress induced
transcatheter aortic valve replacement